» Articles » PMID: 1702928

Localization of Urokinase-type Plasminogen Activator in Stromal Cells in Adenocarcinomas of the Colon in Humans

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1991 Jan 1
PMID 1702928
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Human colon adenocarcinomas and adjacent normal colon tissues were stained immunohistochemically with three different monoclonal antibodies and one preparation of polyclonal antibodies against each of the two plasminogen activators, uPA (urokinase type) and tPA (tissue type). The staining patterns seen with the respective sets of antibodies were identical. In all of 10 cases, staining for uPA in the normal colon tissue was confined to scattered fibroblastlike cells in the lamina propria. Other cells, including epithelial and endothelial cells, were uPA negative. All the tumor infiltrates contained many more uPA-positive cells than the normal tissues, but the staining was confined to fibroblastlike cells and endothelial cells in the tumor stroma, while no staining of the malignant epithelial cells was detected. Analysis for uPA by enzyme-linked immunosorbent assay (ELISA) in four cases showed an average uPA content of 0.15 ng uPA/mg protein in the normal colon tissues and 1.6 ng uPA/mg protein in the tumors. Tissue-type plasminogen activator immunoreactivity was confined to endothelial cells in both the normal colon tissue and in the colon carcinomas. These findings may indicate that colon cancer cells recruit stromal cells to produce uPA involved in degradation of the extracellular matrix during invasive growth.

Citing Articles

Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade.

Zhuo J, Tan E, Yan B, Tochhawng L, Jayapal M, Koh S PLoS One. 2012; 7(8):e43594.

PMID: 22927998 PMC: 3424201. DOI: 10.1371/journal.pone.0043594.


Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.

Xu H, Xu Z, Tseng I, Chou F, Chen Y, Wang J Am J Physiol Cell Physiol. 2011; 302(2):C453-62.

PMID: 22031598 PMC: 3328841. DOI: 10.1152/ajpcell.00344.2011.


Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.

Xu Z, Chen Y, Battu A, Wilder P, Weber D, Yu W J Med Chem. 2011; 54(21):7567-78.

PMID: 21966950 PMC: 3214968. DOI: 10.1021/jm200920s.


Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells.

Gratio V, Loriot C, Virca G, Oikonomopoulou K, Walker F, Diamandis E Am J Pathol. 2011; 179(5):2625-36.

PMID: 21907696 PMC: 3204030. DOI: 10.1016/j.ajpath.2011.07.016.


Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.

Kim T, Song K, Li G, Choi H, Park H, Lim K BMC Cancer. 2006; 6:211.

PMID: 16916471 PMC: 1563482. DOI: 10.1186/1471-2407-6-211.


References
1.
Stephens R, Pollanen J, Tapiovaara H, Leung K, Sim P, Salonen E . Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989; 108(5):1987-95. PMC: 2115548. DOI: 10.1083/jcb.108.5.1987. View

2.
Boyd D, Florent G, Chakrabarty S, Brattain D, Brattain M . Alterations of the biological characteristics of a colon carcinoma cell line by colon-derived substrata material. Cancer Res. 1988; 48(10):2825-31. View

3.
Ellis V, Scully M, Kakkar V . Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem. 1989; 264(4):2185-8. View

4.
Gelister J, Lewin M, Driver H, Savage F, Mahmoud M, Gaffney P . Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?. Gut. 1987; 28(7):816-21. PMC: 1433066. DOI: 10.1136/gut.28.7.816. View

5.
Blasi F, Vassalli J, Dano K . Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987; 104(4):801-4. PMC: 2114431. DOI: 10.1083/jcb.104.4.801. View